Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Exercise  COVID-19 treatment studies for Exercise  C19 studies: Exercise  Exercise   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Long COVID 38% Improvement Relative Risk Long COVID (b) 4% c19early.com/ex Paul et al. Exercise for COVID-19 Prophylaxis Favors exercise Favors inactivity
Paul, 1,811 patient exercise study: 38% improved recovery [p=0.16] https://c19p.org/paulex
copied to clipboard
Health behaviours the month prior to COVID-19 infection and the development of self-reported long COVID and specific long COVID symptoms: A longitudinal analysis of 1,811 UK adults
Paul et al., medRxiv, doi:10.1101/2022.04.12.22273792 (Preprint)
13 Apr 2022    Source   PDF   Share   Tweet
Retrospective 1,811 COVID-19 patients in the UK, showing lower risk of self-reported long COVID with 3+ hours of exercise per week in the month before infection, without statistical significance (p=0.16).
risk of long COVID, 38.1% lower, RR 0.62, p = 0.16, adjusted per study, odds ratio converted to relative risk, 3+ hours per week vs. none, multivariable, model 4, control prevalance approximated with overall prevalence.
risk of long COVID, 4.1% lower, RR 0.96, p = 0.89, adjusted per study, odds ratio converted to relative risk, ≤2 hours per week vs. none, multivariable, model 4, control prevalance approximated with overall prevalence.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Paul et al., 13 Apr 2022, retrospective, United Kingdom, preprint, survey, 2 authors.
Contact: e.paul@ucl.ac.uk.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperExerciseAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit